Lg Life Sciences, Limited

Other

Lg Chem, Ltd

Sang Dae Lee

Sang Hoon Kim

Gyo Hyun Hwang

Koo Lee

Soo Yong Chung

Dong Sup Shim

Hyun Min Lee

Sang Pil Moon

Sung Pil Choi

In Ae Ahn

Young Kwan Kim

Hyun Ho Lee

Eun Sil Choi

Hyun Woo Joo

Sang Yun Park

Chang Seok Lee

Hyeon Joo Yim

Seung Yup Paek

Seung Wan Kang

Byung Gyu Kim

Vasily Artemov

Deog Young Choi

Sung Wook Kim

Yong Hwa Ha

Min Kyung Yoon

Ok Ku Park

Bo Seung Choi

Oeuk Park

Mi Sook Shin

Myoung Yeol Kim

Sang Hyup Lee

Youn Hoa Kim

Jung Ae Lee

Ae Ri Park

Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Biaryl derivative as GPR120 agonist

A moxibustion apparatus includes: a case; a heat storage unit arranged inside the case and including a heat storage material, a heat insulating member covering an outer surface of the heat storage material, an exposed portion exposed to the outside of the heat insulating member, a heating coil embedded in the heat storage material and electrically heated, and a charging terminal that has one side exposed to the outside of the case and is connected to an external power source to provide power to the heating coil; and a moxibustion unit configured to receive heat accumulated in the heat storage material through the exposed portion to locally heat acupuncture points of a user's abdomen, and including a protrusion portion that protrudes to have an end portion thereof formed into a spherical shape or a gently curved shape and is exposed to the outside of the case.

Moxibustion device

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

Thioaryl derivatives as GPR120 agonists

The present invention relates to a compound having a good agonistic activity to melanocortin receptor, or pharmaceutically acceptable salt or isomer thereof, and an agonistic composition for melanocortin receptor comprising the same as an active ingredient.

Melanocortin receptor agonists

The present invention relates to a compound of the following formula 1, pharmaceutically acceptable salt and isomer thereof effective as agonist of melanocortin receptor, and an agonistic composition of melanocortin receptor comprising the same as active ingredient.

Growing community of inventors

Daejeon, South Korea

Sang Dae Lee